



Nanomaterial-Based Contrast Agents for Biomedical Imaging

Guest Editors:

Dr. Bing Guo

School of Science, Harbin
Institute of Technology,
Shenzhen 518055, China

Dr. Tingting Peng

College of Pharmacy, Jinan
University, Guangzhou, China

Deadline for manuscript
submissions:

31 March 2024

Message from the Guest Editors

Dear Colleagues,

Precision imaging is critical for the theranostics of diseases, as it provides insightful guidance for medical personnel to define pathological processes and manage diseases. Nowadays, nanomaterials have emerged as promising alternatives to conventional contrast agents for biomedical imaging since they offer high-fidelity imaging due to an improved delivery efficiency and accumulation in the diseased tissues. With the assistance of advanced imaging techniques, these nanomaterials could provide diverse imaging modalities, such as fluorescence imaging, photoacoustic imaging, magnetic resonance imaging, micro-CT imaging, X-ray imaging, etc. The theranostic performance of nanomaterials could be improved through the delicate tuning of the target ability, responsive release behavior, quantum yield, etc. Therefore, nanomaterials hold great promise for precision theranostics of diseases.

This Special Issue aims to highlight the recent advances in the development of nanomaterials for contrast agents and biomedical imaging. Original research papers and reviews papers are all welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access:— free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[@Biomed_MDPI](https://twitter.com/Biomed_MDPI)